On April 7, Idera Pharmaceuticals Inc (NASDAQ:IDRA) presented new pre-clinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the growing body of research which supports the Company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The findings were presented in a poster session titled “Immune Modulatory Agents and Interventions” at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved down -9.14% in last trading session and was closed at $3.28, while trading in range of $3.24 – 3.77. Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -29.16%.
Datawatch Corporation (NASDAQ:DWCH) announced preliminary results for its second fiscal quarter ended March 31, 2014. The Company anticipates total revenue for the second quarter will be between $7.8 and $8.0 million, and Non-GAAP net loss between $3.1 million and $3.3 million. This compares to total revenue of $6.83 million and Non-GAAP net income of $389,000 for the second fiscal quarter of 2013. Non-GAAP results exclude the effects of the non-cash amortization associated with the purchase of certain intellectual property and other intangible assets, non-cash stock compensation costs and in the 2014 second quarter, a one-time non-cash charge associated with the unamortized debt discount relating to the payoff of the Company’s indebtedness under its credit facility with Massachusetts Capital Resource Company. Datawatch Corporation (NASDAQ:DWCH) weekly performance is -40.44%. On last trading day company shares ended up $14.67. Datawatch Corporation (NASDAQ:DWCH) distance from 50-day simple moving average (SMA50) is -49.72%. Analysts mean target price for the company is $38.75.
Pacific Ethanol Inc (NASDAQ:PEIX) announced that on April 8, 2014 it closed its previously announced underwritten public offering of 1,750,000 shares of its common stock at a public offering price of $16.00 per share, for gross offering proceeds of $28.0 million. Pacific Ethanol Inc (NASDAQ:PEIX) shares after opening at $14.31 on last trade day and at the end of the day closed at $14.15. Company price to sales ratio in past twelve months was calculated as 0.31 and price to cash ratio as 53.63. Pacific Ethanol Inc (NASDAQ:PEIX) showed a negative weekly performance of -5.10%.
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) common stock between November 22, 2013 and March 13, 2014. CytRx Corporation (NASDAQ:CYTR) shares advanced 0.63% in last trading session and ended the day on $3.19. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 11.15%.